Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

SHA:603707 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct 13, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	16,657	21,439	24,169	29,075	52,058	32,706
Market Cap Growth	-18.37%	-11.29%	-16.87%	-44.15%	59.17%	10.12%
Enterprise Value	16,757	21,794	25,024	30,396	54,143	34,595
Last Close Price	10.31	13.15	14.74	17.58	31.32	20.07
PE Ratio	23.87	25.95	-	26.65	49.14	40.57
Forward PE	15.86	17.95	19.44	19.56	38.80	33.70
PS Ratio	4.43	5.46	6.15	7.83	14.12	11.22
PB Ratio	2.52	3.30	4.17	4.72	9.64	8.73
P/TBV Ratio	2.72	3.56	4.39	4.91	10.13	9.35
P/FCF Ratio	23.22	21.56	20.14	231.92	214.34	-
P/OCF Ratio	12.76	14.28	14.93	48.83	76.15	-
EV/Sales Ratio	4.46	5.56	6.37	8.19	14.69	11.87
EV/EBITDA Ratio	16.53	19.19	-	26.18	40.86	34.17
EV/EBIT Ratio	21.00	22.63	-	29.76	43.96	37.28
EV/FCF Ratio	23.36	21.92	20.85	242.46	222.93	-
Debt / Equity Ratio	0.31	0.32	0.45	0.48	0.38	0.87
Debt / EBITDA Ratio	2.04	1.83	-	2.56	1.55	3.22
Debt / FCF Ratio	2.88	2.09	2.17	23.70	8.45	-
Asset Turnover	0.39	0.41	0.40	0.41	0.46	0.46
Inventory Turnover	0.57	0.54	0.67	0.34	0.34	0.32
Quick Ratio	1.33	1.59	0.94	0.96	0.88	0.80
Current Ratio	2.66	3.41	2.35	3.07	3.06	2.41
Return on Equity (ROE)	11.17%	13.45%	-3.17%	18.78%	23.26%	23.61%
Return on Assets (ROA)	5.12%	6.33%	-2.13%	7.00%	9.66%	9.06%
Return on Capital (ROIC)	5.72%	7.10%	-2.37%	7.70%	10.65%	10.19%
Return on Capital Employed (ROCE)	11.30%	12.90%	-	14.00%	20.70%	18.90%
Earnings Yield	4.25%	3.85%	-0.78%	3.75%	2.04%	2.46%
FCF Yield	4.31%	4.64%	4.96%	0.43%	0.47%	-2.63%
Dividend Yield	0.96%	0.76%	0.68%	0.65%	0.37%	0.44%
Payout Ratio	53.55%	25.81%	-	20.78%	18.10%	32.40%
Buyback Yield / Dilution	-3.11%	-4.66%	3.03%	-2.98%	0.43%	-0.94%
Total Shareholder Return	-2.15%	-3.90%	3.71%	-2.32%	0.80%	-0.50%

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.